ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea (PACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01755091
Recruitment Status : Completed
First Posted : December 21, 2012
Results First Posted : December 22, 2017
Last Update Posted : December 22, 2017
Sponsor:
Collaborators:
Northwestern University
University of Chicago
Hektoen Institute for Medical Research
Information provided by (Responsible Party):
David W. Carley, University of Illinois at Chicago

Brief Summary:
This is a proof of concept study to determine the safety and efficacy of dronabinol for the treatment of obstructive sleep apnea syndrome (OSA).

Condition or disease Intervention/treatment Phase
Sleep Apnea, Obstructive Drug: Dronabinol Drug: Placebo (for Dronabinol) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial
Study Start Date : February 2013
Actual Primary Completion Date : June 2016
Actual Study Completion Date : December 31, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea
Drug Information available for: Dronabinol
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: Sugar Pill
Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Drug: Placebo (for Dronabinol)
Experimental: 2.5 mg/day
Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Drug: Dronabinol
Experimental: 10 mg/day
Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Drug: Dronabinol



Primary Outcome Measures :
  1. Change in Apnea/Hypopnea Index (AHI) [ Time Frame: Baseline and Week 6 ]
    Change in AHI derived as: AHI (end of treatment) minus AHI (pre-treatment)

  2. Change in Epworth Sleepiness Scale (ESS) [ Time Frame: Baseline and Week 6 ]
    Change in ESS derived as: ESS (end of treatment) minus ESS (pre-treatment). The ESS scale has a range of 0 to 24, with 0 representing the least degree of sleepiness and 24 the greatest degree of sleepiness. There are no subscales.

  3. Change in Sleep Latency: Maintenance of Wakefulness Test (MWT) [ Time Frame: Baseline and Week 6 ]
    Change in MWT derived as: MWT (end of treatment) minus MWT (pre-treatment). The Maintenance of Wakefulness Test measures a person's ability to stay awake in a quiet, dark and nonstimulating room for a period of time.


Secondary Outcome Measures :
  1. Tolerability by Treatment Satisfaction Questionnaire for Medications (TSQM) Overall Score. [ Time Frame: Week 6 ]
    The TSQM measures a person's satisfaction with treatment based on a 7-point scale ranging from "Extremely Dissatisfied" to "Extremely Satisfied" in response to the question, "Taking all things into account, how satisfied or dissatisfied are you with this medication?".

  2. Adverse Events (AEs) [ Time Frame: Up to 8 weeks ]
    AEs will be evaluated and tracked throughout subject participation (up to 8 weeks)

  3. Change in Desaturation Time (DT) [ Time Frame: 6 weeks ]
    Change in DT (total minutes with arterial oxygen saturation below 85% during 8-hour polysomnography) derived as: DT (end of treatment) minus DT (pre-treatment)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult 21 to 64 years of age;
  • 15≤AHI ≤ 50 on screening polysomnogram (PSG)
  • ESS score ≥ 7
  • Able to understand and complete informed consent and all study assessments and forms, presented in an English-speaking format;
  • Women of child-bearing potential (WCBP) must have a negative urine pregnancy test. In addition sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable or implantable hormonal contraceptive; tubal ligation; intra-uterine devices; barrier contraceptive with spermicide; or vasectomized partner).

Exclusion Criteria:

  • Arterial oxygen saturation < 75% for > 5% of sleep period time on screening PSG;
  • Occupation or life situation that may impart risk by study participation (e.g. commercial driver, pilot, police officer, fireman);
  • Motor vehicle accident or "near-miss" related to sleepiness (self-report) within 2 years of the first dose of study drug (Day 8);
  • Body mass index > 45 kg/m2
  • Severe obstructive sleep apnea syndrome (OSAS) that, based on the clinical judgment of the Investigator, precludes delaying positive airway pressure treatment;
  • History of shift work or rotating shifts within the month prior to the first dose of study drug (Day 8);
  • Prior upper airway surgery for snoring or OSAS as an adult (≥ 18 years of age);
  • Prior non-invasive treatment for OSAS within 6 months prior to the first dose of study drug (Day 8);
  • Major surgery within 6 months prior to the first dose of study drug (Day 8);
  • Bariatric surgery within 2 years prior to the first dose of study drug (Day 8). If post-bariatric surgery, weight must be stable ±5% (self-report) for at least 6 months prior to first dose of study drug (Day 8).
  • Any form of medically managed weight loss program within 6 months prior to the first dose of study drug (Day 8);
  • Significant defect in nasal patency due to anatomical abnormalities or uncontrolled or recurrent episodes of rhinitis;
  • Any clinically significant unstable or progressive medical condition;
  • Any primary sleep disorder other than OSAS as determined by history, physical examination, or Visit 2 PSG (after 7-day screening run-in period);
  • Clinically significant or uncontrolled: chronic obstructive pulmonary disease (COPD), cardiovascular disease, gastrointestinal, respiratory, pancreatic, hepatic, renal, hematologic, endocrine [including insulin-dependent diabetes mellitus (IDDM)], neurological, urogenital, connective tissue, dermatological, thyroid, or other medical disorder;
  • Any clinically significant psychiatric disorder;
  • History of seizure disorder;
  • Treatment with any prescription antidepressant medication within 1 month prior to the first dose of study drug (Day 8);
  • Treatment with sedatives, hypnotics or other psychoactive drugs within 30 days prior to the first dose of study drug (Day 8);
  • Any complete blood count (CBC) or liver function test (LFT) laboratory value outside the normal range which, in the clinical judgment of the Investigator renders a subject inappropriate for randomization to treatment;
  • Pregnancy [as demonstrated by positive urine human chorionic gonadotropin (hCG) test] or lactation;
  • Allergic to cannabinoids or sesame oil;
  • History of substance abuse (including alcohol abuse or dependence) or laboratory evidence of drug abuse on the Visit 1 drug-screening panel;
  • Use of dietary supplements which in the judgment of the Investigator may impact sleep or breathing behaviors;
  • Average daily caffeine consumption > 500 mg/day (~5 cups of coffee);
  • Average weekly alcohol consumption > 10 units;
  • Unwillingness to abstain from caffeine and alcohol on all days when overnight or daytime testing will be performed;
  • Participation in any other investigational protocol within the 30 days prior to the first dose of study drug (Day 8);
  • Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he or she were to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01755091


Locations
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
University of Illinois at Chicago
Northwestern University
University of Chicago
Hektoen Institute for Medical Research
Investigators
Principal Investigator: David W Carley, PhD University of Illinois at Chicago

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David W. Carley, Professor, University of Illinois at Chicago
ClinicalTrials.gov Identifier: NCT01755091     History of Changes
Other Study ID Numbers: UM1HL112856 2011-06400
UM1HL112856 ( U.S. NIH Grant/Contract )
First Posted: December 21, 2012    Key Record Dates
Results First Posted: December 22, 2017
Last Update Posted: December 22, 2017
Last Verified: November 2017

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Dronabinol
Hallucinogens
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Cannabinoid Receptor Agonists
Cannabinoid Receptor Modulators
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists